SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| Phesgo | 80,40 mg/ml,mg/ml | Solution for injection · Subcutaneous use | 1 Vial | SAR 25814.85 | Biological · Prescription | F.Hoffmann-La Roche Ltd. | Valid |
| Phesgo | 60,60 mg/ml,mg/ml | Solution for injection · Subcutaneous use | 1 Vial | SAR 15636.80 | Biological · Prescription | F.Hoffmann-La Roche Ltd. | Valid |
Indications — CHI Daman Drug Formulary
BILIARY TRACT CANCER; COLORECTAL CANCER-ADVANCED/ METASTATIC
EMA European Union — centrally authorised medicines
Phesgo Roche Registration GmbH · Authorised · authorised 21 Dec 2020 · ATC L01XY
Therapeutic indication (EMA)
Early breast cancer (EBC) Phesgo is indicated for use in combination with chemotherapy in: the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence Metastatic breast cancer (MBC) Phesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| PERJETA-HERCEPTIN | 02405024 | 440 MG / VIAL; 420 MG / 14 ML | SOLUTION; KIT; POWDER FOR SOLUTION · INTRAVENOUS | HOFFMANN-LA ROCHE LIMITED |
| PHESGO | 02512912 | 40 MG / ML; 80 MG / ML | SOLUTION · SUBCUTANEOUS | HOFFMANN-LA ROCHE LIMITED |
| PHESGO | 02512920 | 60 MG / ML; 60 MG / ML | SOLUTION · SUBCUTANEOUS | HOFFMANN-LA ROCHE LIMITED |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.